Explore the Agenda
*Please note, attendance at the workshops/engagers is subject to availability and approval by the session partner.
Kick off your summit experience by registering your interest to join Myriad Genetics, Personalis, Natera and Guardant Health for deep-dive engagers designed to give you an inside look at their latest technologies, how they are being applied across biopharma, and the exciting impact they are already having on the field.
These workshops go beyond standard presentations – they are built to be interactive, practical and directly relevant to your work. You’ll gain early access to insights that will shape the discussions across the main conference days, while having the chance to put your own questions directly to the experts driving these advances.
09:30 - 11:30
Introducing Myriad’s Ultrasensitive Tumor Informed MRD Assay
Dale Muzzey, Tadayoshi Hashimoto, Hosein Kouros-Mehr, Lou Welebob
Join this deep-dive session to understand how ultrasensitive, tumor-informed MRD testing is being applied across real clinical and development settings. Hear how leading experts are translating MRD data into actionable decisions across patient management, trial design, and therapeutic development. Walk away with a clear view of where MRD delivers value today and how to apply it across your own programs.
12:00 - 14:30
Accelerating Clinical Timelines: Using Ultrasensitive MRD to Accelerate Clinical
Development
Stephane Mouradian, Jyoti Mayadev, Deepshikha Bhandari
- Accelerating Approvals: The evolving role of MRD as an intermediate endpoint reasonably likely to
predict clinical benefit in oncology - The Power of Certainty: Utilizing ultrasensitive MRD testing to guide clinical decisions
- The Personalis Ecosystem: Integrating NeXT Personal® for a comprehensive view of cancer dynamics - real-time variant tracker and plasma and tumor
15:00 - 17:30
Unlocking the Next Level of Ultrasensitivity with Enhanced Variants
David Kurtz, Jeff Gregg, Dejan Knezevic, Eser Kirkizlar
Natera has recently integrated Foresight’s phased-variant technology into the Signatera™ platform, combining ultrasensitive detection below 0.1 ppm with Natera’s market-leading commercial and operational infrastructure for MRD testing. This enhanced version of Signatera™ is offered alongside CLARITY™ and Latitude™, supporting tumor-informed and tissue-free MRD applications.
This engager session will explore how incorporating additional variant classes enables the next level of ultrasensitivity and creates new opportunities for MRD-guided clinical trials.
18:00 - 20:00
Transforming Therapeutic Frontiers: Expert Insights on Novel Epigenomic Biomarkers
Steffan Ho, Zoe June Assaf, Justin Odegaard, Jean-Francois Martini, Ben Herzberg
Discover how biopharma researchers and clinical oncologists are harnessing the power of novel epigenomic biomarkers to pinpoint the right patients most likely to benefit from your therapy refining your therapeutic strategies and ultimately bringing more effective medicine to the patients who need them.